733 related articles for article (PubMed ID: 12403809)
1. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
2. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
5. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
Shah OJ; Wang Z; Hunter T
Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
[TBL] [Abstract][Full Text] [Related]
7. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
11. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.
Uhlmann EJ; Li W; Scheidenhelm DK; Gau CL; Tamanoi F; Gutmann DH
Glia; 2004 Aug; 47(2):180-8. PubMed ID: 15185396
[TBL] [Abstract][Full Text] [Related]
12. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
Gao X; Zhang Y; Arrazola P; Hino O; Kobayashi T; Yeung RS; Ru B; Pan D
Nat Cell Biol; 2002 Sep; 4(9):699-704. PubMed ID: 12172555
[TBL] [Abstract][Full Text] [Related]
13. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.
Tee AR; Anjum R; Blenis J
J Biol Chem; 2003 Sep; 278(39):37288-96. PubMed ID: 12867426
[TBL] [Abstract][Full Text] [Related]
15. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
Harrington LS; Findlay GM; Gray A; Tolkacheva T; Wigfield S; Rebholz H; Barnett J; Leslie NR; Cheng S; Shepherd PR; Gout I; Downes CP; Lamb RF
J Cell Biol; 2004 Jul; 166(2):213-23. PubMed ID: 15249583
[TBL] [Abstract][Full Text] [Related]
16. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
17. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex.
Shah OJ; Hunter T
J Biol Chem; 2004 May; 279(20):20816-23. PubMed ID: 14993219
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
20. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
